Skip to main content
SpringerLink
Log in

Botulinum Toxin for Overactive Bladder

  • Chapter
  • First Online:
Female Urinary Incontinence

  • 875 Accesses

Abstract

Onabotulinum toxin type A (BTX A) is widely used as cystoscopic injections as third-line treatments for idiopathic urinary urgency/frequency otherwise known as overactive bladder (OAB). Many urologists know the common indications and injection parameters. In this chapter, we will review some of the additional parameters and nuances that are not widely covered. Additionally, we will review the other botulinum toxins that are available but generally not used in urology, but might be on the horizon. Finally, some nuanced injection techniques that might help the advanced providers that are looking to fine-tune injections for particular patient parameters.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

ACh:

Acetylcholine

ASB:

Asymptomatic bacteriuria

BTXA:

Onabotulinum toxin A

DMSO:

Dimethyl sulfoxide

GRA:

Global Response Assessment

ICS:

International Continence Society

NLUTD:

Neurogenic lower urinary tract dysfunction

OAB:

Overactive bladder

PVR:

Post void residual

SNM:

Sacral neuromodulation

U:

Units

UTI:

Urinary tract infection

UUI:

Urgency urinary incontinence

References

  1. Haylen BT, Freeman RM, Swift SE, Cosson M, Davila GW, Deprest J, et al. An International Urogynecological Association (IUGA) /International Continence Society (ICS) joint terminology and classification of the complications related directly to the insertion of prostheses (meshes, implants, tapes) & grafts in female pelvic flo. Int Urogynecol J. 2011;22(1):3–15.

    Article  PubMed  Google Scholar 

  2. Gormley EA, Lightner DJ, Faraday M, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. J Urol [Internet]. 2015;193(5):1572–80. Available from: https://doi.org/10.1016/j.juro.2015.01.087

    Article  Google Scholar 

  3. Coelho A, Cruz F, Cruz CD, Avelino A. Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. Eur Urol. 2012;61(6):1178–84.

    Article  CAS  PubMed  Google Scholar 

  4. Chen JL, Kuo HC. Clinical application of intravesical botulinum toxin type a for overactive bladder and interstitial cystitis. Investig Clin Urol. 2020;61:S33–42.

    Article  PubMed  Google Scholar 

  5. Walker TJ, Dayan SH. Comparison and overview of currently available neurotoxins. J Clin Aesthet Dermatol. 2014;7(2):31–9.

    PubMed  PubMed Central  Google Scholar 

  6. Stoehrer M, Wolff A, Kramer G, Steiner R, Löchner-Ernst D, Leuth D, et al. Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years. Urol Int. 2009;83(4):379–85.

    Article  CAS  PubMed  Google Scholar 

  7. Ravindra P, Jackson BL, Parkinson RJ. Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox®) or abobotulinumtoxinA (Dysport®) make a difference? BJU Int. 2013;112(1):94–9.

    Article  CAS  PubMed  Google Scholar 

  8. Craciun M, Irwin PP. Outcomes for intravesical abobotulinumtoxin A (Dysport) treatment in the active management of overactive bladder symptoms—a prospective study. Urology [Internet]. 2019;130:54–8. Available from: https://doi.org/10.1016/j.urology.2019.04.018

    Article  Google Scholar 

  9. Abeywickrama L, Arunkalaivanan A, Quinlan M. Repeated botulinum toxin type A (Dysport®) injections for women with intractable detrusor overactivity: a prospective outcome study. Int Urogynecol J Pelvic Floor Dysfunct. 2014;25(5):601–5.

    Article  Google Scholar 

  10. Bottet F, Peyronnet B, Boissier R, Reiss B, Previnaire JG, Manunta A, et al. Switch to abobotulinum toxin A may be useful in the treatment of neurogenic detrusor overactivity when intradetrusor injections of onabotulinum toxin A failed. Neurourol Urodyn. 2018;37(1):291–7.

    Article  CAS  PubMed  Google Scholar 

  11. Apostolidis A, Cameron AP. Neurourological management after failed Intradetrusor onabotulinumtoxinA injections. Eur Urol Focus [Internet]. 2020;6(5):814–6. Available from: https://doi.org/10.1016/j.euf.2019.10.003

    Article  Google Scholar 

  12. Asafu-Adjei D, Small A, McWilliams G, Galea G, Chung D, Pak J. The intravesical injection of highly purified botulinum toxin for the treatment of neurogenic detrusor overactivity. Can Urol Assoc J. 2019;14(10):520–6.

    Article  Google Scholar 

  13. Pereira e Silva R, Ponte C, Lopes F, Palma dos Reis J. Alkalinized lidocaine solution as a first-line local anesthesia protocol for intradetrusor injection of onabotulinum toxin A: results from a double-blinded randomized controlled trial. Neurourol Urodyn. 2020;39(8):2471–9.

    Article  CAS  PubMed  Google Scholar 

  14. Liao C-H, Chen S-F, Kuo H-C. Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: a prospective randomized comparative study. Neurourol Urodyn. 2016;35:717–33.

    Article  CAS  PubMed  Google Scholar 

  15. Martínez-Cuenca E, Bonillo MA, Morán E, Broseta E, Arlandis S. Onabotulinumtoxina re-injection for refractory detrusor overactivity using 3–4 injection sites: results of a pilot study. Urology. 2020;137:50–4.

    Article  PubMed  Google Scholar 

  16. Chen P-Y, Lee W-C, Wang H-J, Chuang YC. Therapeutic efficacy of onabotulinumtoxinA delivered using various approaches in sensory bladder disorder. Toxins (Basel). 2020;12(75):1–11.

    CAS  Google Scholar 

  17. Kuo HC, Liu HT, Chuang YC, Birder LA, Chancellor MB. Pilot study of liposome-encapsulated onabotulinumtoxinA for patients with overactive bladder: a single-center study. Eur Urol [Internet]. 2014;65(6):1117–24. Available from: https://doi.org/10.1016/j.eururo.2014.01.036

    Article  CAS  Google Scholar 

  18. Tyagi P, Li Z, Chancellor M, De Groat WC, Yoshimura N. Sustained intravesical drug delivery using thermosensitive hydrogel. Pharm Res. 2004;21(5):832–7.

    Article  CAS  PubMed  Google Scholar 

  19. El Shatoury MG, DeYoung L, Turley E, Yazdani A, Dave S. Early experimental results of using a novel delivery carrier, hyaluronan-phosphatidylethanolamine (HA-PE), which may allow simple bladder instillation of botulinum toxin A as effectively as direct detrusor muscle injection. J Pediatr Urol [Internet]. 2018;14(2):172.e1–6. Available from: https://doi.org/10.1016/j.jpurol.2017.11.016

    Article  Google Scholar 

  20. Petrou SP, Parker AS, Crook JE, Rogers A, Metz-Kudashick D, Thiel DD. Botulinum A toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study. Mayo Clin Proc [Internet]. 2009;84(8):702–6. Available from: https://doi.org/10.4065/84.8.702

    Article  CAS  Google Scholar 

  21. Ladi-Seyedian SS, Sharifi-Rad L, Kajbafzadeh AM. Intravesical electromotive botulinum toxin type “A” administration for management of urinary incontinence secondary to neuropathic detrusor overactivity in children: long-term follow-up. Urology [Internet]. 2018;114:167–74. Available from: https://doi.org/10.1016/j.urology.2017.11.039

    Article  Google Scholar 

  22. Nageib M, Zahran MH, El-Hefnawy AS, Barakat N, Awadalla A, Aamer HG, et al. Low energy shock wave-delivered intravesical botulinum neurotoxin-A potentiates antioxidant genes and inhibits proinflammatory cytokines in rat model of overactive bladder. Neurourol Urodyn. 2020;39(8):2447–54.

    Article  CAS  PubMed  Google Scholar 

  23. Syan R, Briggs MA, Olivas JC, Srivastava S, Comiter CV, Dobberfuhl AD. Transvaginal ultrasound guided trigone and bladder injection: a cadaveric feasibility study for a novel route of intradetrusor chemodenervation. Investig Clin Urol. 2019;60(1):40–5.

    Article  PubMed  Google Scholar 

  24. Flynn MK, Amundsen CL, Perevich MA, Liu F, Webster GD. Outcome of a randomized, double-blind, placebo controlled trial of botulinum a toxin for refractory overactive bladder. J Urol [Internet]. 2009;181(6):2608–15. Available from: https://doi.org/10.1016/j.juro.2009.01.117

    Article  CAS  Google Scholar 

  25. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol. 2007;177(6):2231–6.

    Article  CAS  PubMed  Google Scholar 

  26. Kalsi V, Apostolidis A, Gonzales G, Elneil S, Dasgupta P, Fowler CJ. Early effect on the overactive bladder symptoms following botulinum neurotoxin type a injections for detrusor overactivity. Eur Urol. 2008;54(1):181–7.

    Article  CAS  PubMed  Google Scholar 

  27. Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, et al. Refractory idiopathic urge urinary incontinence and botulinum a injection. J Urol. 2008;180(1):217–22.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Dmochowski R, Chapple C, Nitti VW, Chancellor M, Everaert K, Thompson C, et al. Efficacy and safety of onabotulinumtoxina for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial. J Urol [Internet]. 2010;184(6):2416–22. Available from: https://doi.org/10.1016/j.juro.2010.08.021

    Article  CAS  Google Scholar 

  29. Kennelly M, Dmochowski R, Schulte-Baukloh H, Ethans K, Del Popolo G, Moore C, et al. Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: final results of a long-term extension study. Neurourol Urodyn. 2017;36(2):368–75.

    Article  CAS  PubMed  Google Scholar 

  30. Rovner E, Kennelly M, Shulte-Baukloh H, Zhou J, Haag-Molkenteller C, Dasgupta P. Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxinA in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder. Neurourol Urodyn. 2011;30:556–62.

    Article  CAS  PubMed  Google Scholar 

  31. Chapple C, Sievert KD, Macdiarmid S, Khullar V, Radziszewski P, Nardo C, et al. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol [Internet]. 2013;64(2):249–56. Available from: https://doi.org/10.1016/j.eururo.2013.04.001

    Article  CAS  Google Scholar 

  32. Nitti VW, Dmochowski R, Herschorn S, Sand P, Thompson C, Nardo C, et al. OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. J Urol [Internet]. 2013;189(6):2186–93. Available from: https://doi.org/10.1016/j.juro.2012.12.022

    Article  CAS  Google Scholar 

  33. Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MFR, Menefee SA, et al. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. N Engl J Med. 2012;367(19):1803–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Amundsen CL, Richter HE, Menefee SA, Komesu YM, Arya LA, Gregory WT, et al. Onabotulinumtoxin a vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA. 2016;316(13):1366–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Amundsen CL, Komesu YM, Chermansky C, Gregory WT, Myers DL, Honeycutt EF, et al. Two-year outcomes of sacral neuromodulation versus onabotulinumtoxinA for refractory urgency urinary incontinence: a randomized trial [figure presented]. Eur Urol [Internet]. 2018;74(1):66–73. Available from: https://doi.org/10.1016/j.eururo.2018.02.011

    Article  CAS  Google Scholar 

  36. Baron M, Perrouin-Verbe MA, Lacombe S, Paret F, Le Normand L, Cornu JN. Efficacy and tolerance of botulinum toxin injections after sacral nerve stimulation failure for idiopathic overactive bladder. Neurourol Urodyn. 2020;39(3):1012–9.

    Article  CAS  PubMed  Google Scholar 

  37. Wells H, Luton O, Simpkin A, Bullock N, KandaSwamy G, Younis A. Intravesical injection of botulinum toxin a for treatment of overactive bladder in anticoagulated patients: is it safe? Turk J Urol. 2020;46(6):481–7.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Derisavifard S, Giusto LL, Zahner P, Rueb JJ, Goldman HB. Safety of intradetrusor onabotulinumtoxinA (BTX-A) injection in the asymptomatic patient with a positive urine dip. Urology. 2020;135:38–43.

    Article  PubMed  Google Scholar 

  39. Aharony S, Przydacz M, Van Ba OL, Corcos J. Does asymptomatic bacteriuria increase the risk of adverse events or modify the efficacy of intradetrusor onabotulinumtoxinA injections? Neurourol Urodyn. 2020;39(1):203–10.

    Article  CAS  PubMed  Google Scholar 

  40. Dressler D. Clinical presentation and management of antibody-induced failure of botulinum toxin therapy. Mov Disord. 2004;19(Suppl. 8):92–100.

    Article  Google Scholar 

  41. Schulte-Baukloh H, Bigalke H, Miller K, Heine G, Pape D, Lehmann J, et al. Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure. Int J Urol. 2008;15(5):407–15.

    Article  CAS  PubMed  Google Scholar 

  42. Linsenmeyer TA. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review. J Spinal Cord Med [Internet]. 2013;36(5):402–19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23941788

    Article  PubMed Central  Google Scholar 

  43. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord. 2002;40(11):599–600.

    Article  CAS  PubMed  Google Scholar 

  44. Grosse J, Kramer G, Stöhrer M. Success of repeat detrusor injections of botulinum A toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol. 2005;47(5):653–9.

    Article  CAS  PubMed  Google Scholar 

  45. Kalsi V, Gonzales G, Popat R, Apostolidis A, Elneil S, Dasgupta P, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol. 2007;62(5):452–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery, University of Utah Health, Salt Lake City, UT, USA

    Sophia Janes & Sara M. Lenherr

  2. Urology, University of Michigan, Ann Arbor, MI, USA

    Anne P. Cameron

Authors
  1. Sophia Janes
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sara M. Lenherr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anne P. Cameron
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anne P. Cameron .

Editor information

Editors and Affiliations

  1. Urology, University of Michigan, Ann Arbor, MI, USA

    Anne P. Cameron

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Janes, S., Lenherr, S.M., Cameron, A.P. (2022). Botulinum Toxin for Overactive Bladder. In: Cameron, A.P. (eds) Female Urinary Incontinence. Springer, Cham. https://doi.org/10.1007/978-3-030-84352-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-84352-6_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-84351-9

  • Online ISBN: 978-3-030-84352-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation